The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes

Dual Trigger With Gonadotropin-releasing Hormone Agonist (GnRHa) and Human Chorionic Gonadotropin (hCG) to Optimize ICSI Reproductive Outcomes

NCT01979341•Antalya IVF

View on ClinicalTrials.gov

Summary

The use of antagonist controlled ovarian stimulation protocols has allowed the use of GnRH agonist to be used for final oocyte maturation. The use of GnRH agonist as ovulation trigger has been shown to reduce the risks for ovarian hyperstimulation syndrome (OHSS), but its sole use results in reduced embryo implantation due to luteal phase insufficiency. The combination of GnRH agonist and variable doses of hCG for final oocyte maturation has been shown to overcome the luteal phase insufficiency effecting endometrial receptivity. In this study the investigators will test the hypothesis that using GnRH agonist (0.2mg Triptorelin) and a full dose of hCG (6500IU Ovitrelle) for final oocyte maturation in normoresponders will increase oocyte maturity, embryo quality and embryo implantation and reduce ovarian hyperstimulation syndrome, as compared to the traditional hCG (full dose) alone trigger.

Eligibility

Age

18 - 39 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Age; \< 40 years
•Cycle number; cycles 1 or 2
•Antral follicle count; \>10 and \<25
•BMI; \>18 and \<30
•Normogonadotrophic cycle length; 24 to 25 days
•Male; ejaculated semen only

Exclusion Criteria

•Presence of endocrine disorders; (diabetes mellitus, hyperprolactinemia, thyroid dysfunction, congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary syndrome)
•Previous major uterine surgery (that would affect endometrial receptivity)
•\<5 follicles at the time of trigger
•\<2 full formed blastocyst on day 5 of embryo culture

Locations (1)

Antalya IVF

Antalya, Antalya, Turkey (Türkiye)

Key Dates

Start Date

October 1, 2013

Primary Completion Date

June 1, 2016

Completion Date

September 1, 2016

Last Updated

May 26, 2016

Conditions

PregnancyOvarian Hyperstimulation Syndrome

Interventions

final oocyte maturation trigger

PROCEDURE

Mindfulness-based Intervention Prior to External Cephalic Version

NCT06768060

Breech Presentation in PregnancyExternal Cephalic Version

View study

RECRUITINGPHASE4

Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate

NCT07462065

Infertility TreatmentPregnancy Rates

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 26, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes

Inclusion Criteria

Exclusion Criteria

Mindfulness-based Intervention Prior to External Cephalic Version

Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate

Comparison of Two Salpingectomy Techniques for Sterilization at the Time of Cesarean Delivery

Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation

Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy

Lactoferrin-Based Oral Care for Periodontal Health in Pregnancy